This episode, titled 'Identifying Narcolepsy in Psychiatric Populations,' features panelists discussing the challenges of recognizing narcolepsy in psychiatric populations, where overlapping symptoms of mood dysregulation, fatigue, and attention difficulties can easily redirect clinical attention away from an underlying sleep disorder.
In 'Reviewing the Prevalence and Underdiagnosis of Narcolepsy,' our panel delves into the prevalence and underdiagnosis of narcolepsy, pushing back against the widespread assumption that it is a rare condition.
The 2026 MDA National Ambassador discussed the importance of connecting patients’ experiences with scientific understanding, as well as fostering a sense of community among those living with neuromuscular disease. [WATCH TIME: 2 minutes]
The division chief of neuroimmunology at Brigham and Women’s Hospital provided clinical insights on a recently published study in JAMA Neurology covering EBNA-1 antibodies as a diagnostic clue in neuroinflammatory diseases like multiple sclerosis. [WATCH TIME: 4 minutes]
Experts weigh factor XIa inhibitor asundexian after ischemic stroke, highlighting strong efficacy and safety signals and fueling optimism for Librexia Stroke trial results.
Global trial tests ascendexian after ischemic stroke/TIA, showing low bleeding and raising questions about diversity and real-world fit.
The chief research officer of the Muscular Dystrophy Association spoke on highlights and themes from the organization's 2026 Clinical and Scientific Conference. [WATCH TIME: 9 minutes]
In episode 1, neurologist Catherine Lomen-Hoerth, MD, PhD, is joined by Timothy Miller, MD, PhD, to discuss pivotal long-term data showing tofersen's meaningful impact in patients with SOD1 ALS.
Neurology News Network for the week ending March 21, 2026. [WATCH TIME: 4 minutes]
Healthcare professionals emphasize the importance of partnership in MS treatment, focusing on personalized goals and empowering patients to take control of their health.
Experts share effective communication strategies and metaphors to enhance patient understanding and engagement in managing neurological disorders.
In this final episode, Migvis Monduy, MD, discussed long-term data needed to define vamorolone’s durability, safety, and impact across disease stages, including unanswered questions around bone health, growth, cardiomyopathy, and combination strategies.
The research portfolio director at the Muscular Dystrophy Association highlighted the collaborative spirit, the expanding therapeutic pipeline, and the growing emphasis on patients’ voices in neuromuscular disease on display at MDA 2026. [WATCH TIME: 8 minutes]
In this episode, the panel explores the role of treatment satisfaction questionnaires in NMOSD, discussing how patient-reported experience—alongside efficacy and safety—may shape future prescribing decisions and how complement inhibition could redefine long-term management paradigms.
The child neurologist at Children’s Hospital of Philadelphia discussed the real-world safety data of givinostat use in patients with Duchenne muscular dystrophy at the 2026 MDA Conference. [WATCH TIME: 5 minutes]
In this episode, 'Recognizing Narcolepsy Across the Lifespan', the experts explore the clinical presentation of narcolepsy, beginning with the one symptom universal to all patients: excessive daytime sleepiness. The expert panel notes that sleepiness can manifest differently across individuals, with some patients actively masking it through compensatory behaviors, making it easy to underestimate or overlook.
Welcome back to another Neurology Times Peer Exchange series. In this episode titled, 'Understanding Narcolepsy as More Than a Sleep Disorder', the moderator, Dr. Karl Doghramji, led the conversation about excessive daytime sleepiness as a widespread clinical challenge, with the expert panel narrowing the focus to narcolepsy, a central disorder of hypersomnolence that is frequently missed in practice.
The professor of neurology at Cleveland Clinic’s Mellen Center for MS provided thoughts on how radiologic biomarkers may help shape the next generation of multiple sclerosis clinical trials. [WATCH TIME: 3 minutes]
Global trial tests ascendexian after ischemic stroke/TIA, showing low bleeding and raising questions about diversity and real-world fit.
Early BB-301 gene therapy data show durable swallowing gains and benign safety in OPMD dysphagia, hinting at disease modification.
Experts unpack a global stroke-prevention trial, weighing real-world fit, diversity gaps, reperfusion patients, and surprisingly low bleeding.
A neurologist at Georgetown University, MedStar Health, discussed phase 2/3 data presented at the 2026 MDA Conference that supports efgartigimod as a novel treatment for inflammatory myopathies. [WATCH TIME: 2 minutes]
At the 2026 MDA Conference, a neurologist at Nemours Children's Hospital discussed practical strategies for navigating insurance to ensure patients can access newly available neuromuscular therapies. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending March 14, 2026. [WATCH TIME: 4 minutes]
Effective patient communication transforms complex disease concepts into understandable insights, fostering trust and empowering individuals with MS.
A forward-looking discussion on the continued role of vamorolone as background steroid therapy in patients receiving gene or mutation-specific treatments, including what is known, what remains uncertain, and how clinicians are navigating combination strategies in practice.
Experts discuss the importance of systematic longitudinal follow-up in multiple sclerosis care, emphasizing holistic assessments and cognitive testing for better patient outcomes.
A practical discussion on how vamorolone is being incorporated into Duchenne management, including its role in steroid initiation, reintroduction after prior intolerance, and long-term planning across different stages of disease.
In this episode, the panel discusses the real-world safety signals seen with rituximab—particularly serious and recurrent infections—how to think beyond IgG levels alone, and what clinicians can do to better monitor and mitigate infectious risk while balancing relapse prevention.
The president and chief executive officer of the Biotechnology Innovation Organization shared insights on his keynote speech delivered at MDA 2026, reflecting on the evolving rare disease ecosystem. [WATCH TIME: 3 minutes]
